In cancer, Nrf2 unbinds from Keap1, enters the nucleus, and causes activation of transcription factors, resulting in drug resistance, enhanced cell proliferation, stress adaptation, and activation of metabolic reprogramming [11]. This evidence concerns the gene NFE2L2 and cancer.